Highlights from FutureMed 2013 | Are We Ever Really Out of Office?
New ESC Guidelines for Oral Anticoagulants | Interview with NCDR’s John S. Rumsfeld, MD, PhD
CardioSource WorldNews
vol 2, no 3 / March 2013
A publication of the American College of Cardiology
“VALLEY of
Health Care in Turmoil
Navigating the
BYPASSING
Will greater use of bariatric bypass lead to fewer CABG surgeries?
CardioSource WorldNews
vol 2, no 6 / JUNE 2013
A publication of the American College of Cardiology
DEATH”
PLUS
Chip Lavie: Is There Still Reason To Treat Triglycerides and Low HDL? payaL KohLi: Are We Doctors or Politicians?
CliniCAl news
PLUS
Cardiologists Share Experiences from the Boston Marathon Bombing SPENCER KING: The Way Forward on STEMI
OBESITY
CLINICAL NEWS
Available for the iPad!
6/12/13 10:35 AM
CardioSource.org/CSWN
CardioSource.org/CSWN
ACCEL: How to Choose Patients for TAVR vs. Open AVR
Harold Miller on Costs, Quality and Physician Satisfaction
Increased Clarity on AUC Terminology
ACCEL: HF Monitoring to Improve Outcomes
Hold the Holter: Interview with iRhythm CEO Kevin King
Payal Kohli: The Challenge of International Cardiology
CSWN_Cover_6'13.indd 991
BRILINTA® (ticagrelor) Tablets
WARNING: BLEEDING RISK • BRILINTA, like other antiplatelet agents, can cause signi?cant, sometimes fatal bleeding [see WARNINGS AND PRECAUTIONS and ADVERSE REACTIONS]. • Do not use BRILINTA in patients with active pathological bleeding or a history of intracranial hemorrhage [see CONTRAINDICATIONS]. • Do not start BRILINTA in patients planned to undergo urgent coronary artery bypass graft surgery (CABG). When possible, discontinue BRILINTA at least 5 days prior to any surgery [see WARNINGS AND PRECAUTIONS]. • Suspect bleeding in any patient who is hypotensive and has recently undergone coronary angiography, percutaneous coronary intervention (PCI), CABG, or other surgical procedures in the setting of BRILINTA [see WARNINGS AND PRECAUTIONS]. • If possible, manage bleeding without discontinuing BRILINTA. Stopping BRILINTA increases the risk of subsequent cardiovascular events [see WARNINGS AND PRECAUTIONS]. WARNING: ASPIRIN DOSE AND BRILINTA EFFECTIVENESS • Maintenance doses of aspirin above 100 mg reduce the effectiveness of BRILINTA and should be avoided. After any initial dose, use with aspirin 75-100 mg per day [see WARNINGS AND PRECAUTI ??2?B4???4?5ETD?U2?B???gV??&W67&?&??r??f?&?F?????G?7?V???D??G?7?Vv2&W?'FVB??BR?bF?V?G2G&VFVBv?F?%$???D?B???R?bF?V?G2F???r6???F?w&V??G?7?Vv2W7V????BF???FW&FR????FV?6?G??B?gFV?&W6??fVBGW&??r6??F??VVBG&VF?V?B?'WB?666?????&WV?&VBF?66??F??VF??????R?bF?V?G2F???r%$???DfW'7W2?R?bF?V?G2F???r6???F?w&V???bF?V?BFWfV??2?Wr?&????vVB??"v?'6V?VBG?7?VGW&??rG&VF?V?Bv?F?%$???D?W?6?VFRV?FW&???rF?6V6W2F?B??&WV?&RG&VF?V?B??bG?7?V?2FWFW&??VBF?&R&V?FVBF?%$???D???7V6???2G&VF?V?B?2&WV?&VC?6??F??VR%$???Dv?F??WB??FW''WF??????F?R66R?b??F??W&&?RG?7?V&WV?&??rF?66??F??VF????b%$???D?6??6?FW"&W67&?&??r??F?W"?F??FV?WBvV?B???7V'7GVG????F?V?G2g&???D?V?FW'vV?BV????'?gV?7F???FW7F??r?'&W7V7F?fR?bv?WF?W"F?W?&W?'FVBG?7?V?F?W&Rv2??6?v????6?BF?ffW&V?6R&WGvVV?G&VF?V?Bw&?W2f?"dUc?F?W&Rv2????F?6F????b?GfW'6RVffV7B??V????'?gV?7F???76W76VBgFW"??R???F??"gFW"B?V7Bb???F?2?b6?&???2G&VF?V?B?F?66??F??VF????b%$???Df??B??FW''WF????b%$???DG&VF?V?B??b%$???D?W7B&RFV??&&??F?66??F??VVB?R?r??F?G&VB&?VVF??r?"f?"V?V7F?fR7W&vW'???&W7F'B?B26???2?76?&?R?F?66??F??VF????b%$???Dv?????7&V6RF?R&?6??b??6&F????f&7F????7FV?BF?&??&?6?2??BFVF??7G&??r??&?F?'2?b7?F?6?&??R5?4F?6w&V??"?2?WF&???VB'?5?4B?R?f??BW6Rv?F?7G&??r5?4??&?F?'2?7V6?2F??f?"?6?&?F?&??6?????F??f?"??G&6?????R??WF?6?????R??Vf??F??R??V????f?"?&?F??f?"?6V??f?"?FV?F?&??6???Bf?&?6?????R?6VRG'Vr??FW&7F???2?r???B6???6??&?6???w??"?2???gV??&W67&?&??r??f?&?F?????7?F?6?&??R5?4?FV?B??GV6W'2f??BW6Rv?F??FV?B5?4??GV6W'2?7V6?2&?f????FW??WF?6??R??V??F????6&&??W??R??B?V??&&&?F??6VRG'Vr??FW&7F???2?r?"??B6???6??&?6???w??"?2???gV??&W67&?&??r??f?&?F?????%$?Tb5T??%??b$U45$?$??r??d?$?D???f?"gV??&W67&?&??r??f?&?F????6VR6?vR??6W'B?EdU%4R$T5D???26???6?G&??2W?W&?V?6P?F?Rf????v??rGfW'6R&V7F???2&R?6?F?67W76VBV?6Wv?W&R??F?R?&V??s?(
"G?7?V?6VRv&???w2?B&V6WF???2?R?B???gV??&W67&?&??r??f?&?F????&V6W6R6???6?G&??2&R6??GV7FVBV?FW"v?FV?f'???r6??F?F???2?GfW'6R&V7F???&FW2?'6W'fVB??F?R6???6?G&??2?bG'Vr6???B&RF?&V7F?6??&VBF?&FW2??F?R6???6?G&??2?b??F?W"G'Vr?B????B&Vf?V7BF?R&FW2?'6W'fVB??&7F?6R?%$???D?2&VV?Wf?VFVBf?"6fWG?????&RF??F?V?G2???6?VF??r??&RF??3F?V?G2G&VFVBf?"??&RF???V"?&?VVF??r?D?W6VBF?Rf????v??r&?VVF??r6WfW&?G?6FVv?&??F????(
"???"&?VVB( 2fF???fR?F?&VFV???r?????R?bF?Rf????v??s?fFò??G&7&??ò??G&W&?6&F??&?VVBv?F?6&F?2F???FS????f??V?26??6??"6WfW&R???FV?6???GVRF?&?VVF??r?B&WV?&??r&W76?'2?"7W&vW'??6???6???fW'B?"&V?B&?VVF??r76?6?FVBv?F?FV7&V6R???V??v??&????"??b??&RF??Rr?DòG&?6gW6????bB?"??&RV??G2?v???R&???B?"6?VB&VB&???B6V??2?$$72??f?"&?VVF??r?(
"???"&?VVB( 2?F?W"?????R?bF?Rf????v??s?6?v??f?6?F?F?6&??r?R?r????G&?7V?"v?F?W&??V?Bf?6?????72??6???6???fW'B?"&V?B&?VVF??r76?6?FVBv?F?FV7&V6R???"?b2r?DòG&?6gW6????b"?2V??G2?v???R&???B?"$$72?f?"&?VVF??r?(
"???"&?VVB?&WV?&W2?VF?6???FW'fV?F???F?7F??"G&VB&?VVF??r?R?r??W?7F??2&WV?&??rf?6?BF??VF?6?f6??G?f?"6???r??(
"?????&?VVB????F?W'2?R?r??''V?6??r?&?VVF??rwV?2??????rg&?????V7F???6?FW2?WF2????B&WV?&??r??FW'fV?F????"G&VF?V?B?f?wW&R6??w2???"&?VVF??rWfV?G2?fW"F??R????WfV?G2&RV&??BF??R?b6?&??'??v??w&???4??4$r??B?F?W"&?6VGW&W2?'WBF?R&?6?W'6?7G2GW&??r?FW"W6R?b?F??FV?WBF?W&??f?wW&R?????V?W"W7F??FR?bF??RF?f?'7B?D??FVf??VB( ?F?F????.( ?&?VVF??rWfV?@????D?4D???2?BU4tR7WFR6?&??'?7??G&??W0?%$???D?2%?"?FV?WB??&?F?"??F?6FVBF?&VGV6RF?R&FR?bF?&??&?F?26&F??f67V?"WfV?G2??F?V?G2v?F?7WFR6?&??'?7??G&??R?52??V?7F&?R?v???????5BV?WfF?????6&F????f&7F?????"5BV?WfF?????6&F????f&7F?????%$???D?2&VV?6??v?F?&VGV6RF?R&FR?b6??&??VBV?G???B?b6&F??f67V?"FVF????6&F????f&7F????"7G&??R6??&VBF?6???F?w&V??F?RF?ffW&V?6R&WGvVV?G&VF?V?G2v2G&?fV?'?5bFVF??B?v?F???F?ffW&V?6R??7G&??R???F?V?G2G&VFVBv?F?4???B?6?&VGV6W2F?R&FR?b7FV?BF?&??&?6?2?6VR6???6?7GVF?W2?B???gV??&W67&?&??r??f?&?F?????%$???D?2&VV?7GVF?VB??52??6??&??F???v?F?7?&??????FV??6RF?6W2?b7?&??&?fR?rFV7&V6VBF?RVffV7F?fV?W72?b%$???D?f??B???FV??6RF?6W2?b7?&??&?fR?rF???6VRv&???w2?B&V6WF???2?B6???6?7GVF?W2?B???gV??&W67&?&??r??f?&?F?????D?4tR?BD???5E$D?????F?FR%$???DG&VF?V?Bv?F???r?Gv???rF&?WG2???F??rF?6R?B6??F??VRG&VF?V?Bv?F???rGv?6RF???gFW"F?R???F????F??rF?6R?b7?&???W7V??3#R?r??W6R%$???Dv?F?F?????FV??6RF?6R?b7?&???bsR??r?52F?V?G2v???fR&V6V?fVB??F??rF?6R?b6???F?w&V???&R7F'FVB??%$???D?%$???D6?&RF???7FW&VBv?F??"v?F??WBf??B?F?V?Bv???76W2F?6R?b%$???D6??V?BF?R??R??rF&?WB?F?V?"?W?BF?6R?B?G266?VGV?VBF??R?4??E$??D?4D???0???7F?'??b??G&7&????V??'&?vR%$???D?26??G&??F?6FVB??F?V?G2v?F???7F?'??b??G&7&????V??'&?vR??4??&V6W6R?b??v?&?6??b&V7W'&V?B?4???F??2?V?F????6VR6???6?7GVF?W2?B???gV??&W67&?&??r??f?&?F?????7F?fR&?VVF??r%$???D?26??G&??F?6FVB??F?V?G2v?F?7F?fRF????v?6?&?VVF??r7V6?2WF?2V?6W"?"??G&7&????V??'&?vR?6VRv&???w2?B&V6WF???2?R???BGfW'6R&V7F???2?b????gV??&W67&?&??r??f?&?F?????6WfW&R?WF?2???&?V?B%$???D?26??G&??F?6FVB??F?V?G 2v?F?6WfW&R?WF?2???&?V?B&V6W6R?b&?&&?R??7&V6R??W??7W&R??B?B?2??B&VV?7GVF?VB??F?W6RF?V?G2?6WfW&R?WF?2???&?V?B??7&V6W2F?R&?6??b&?VVF??r&V6W6R?b&VGV6VB7??F?W6?2?b6?wV?F???&?FV??2?6VR6???6??&?6???w??"?2???gV??&W67&?&??r??f?&?F???????W'6V?6?F?f?G?%$???D?26??G&??F?6FVB??F?V?G2v?F???W'6V?6?F?f?G??R?r??v??VFV??F?F?6w&V??"?"??6????V?B?bF?R&?GV7B?6VRGfW'6R&V7F???2?b????gV??&W67&?&??r??f?&?F?????t$???u2?B$T4UD???2vV?W&?&?6??b&?VVF??rG'Vw2F?B??&?B?FV?WBgV?7F?????6?VF??r%$???D??7&V6RF?R&?6??b&?VVF??r?%$???D??7&V6VBF?R?fW&??&?6??b&?VVF??r????"????"?F?6??Wv?Bw&VFW"W?FV?BF??F?B6???F?w&V??F?R??7&V6Rv26VV?f?"????4$r?&V?FVB&?VVF??r?'WB??Bf?"4$r?&V?FVB&?VVF??r?fF??B?fR?F?&VFV???r&?VVF??r&FW2vW&R??B??7&V6VB?6VRGfW'6R&V7F???2?b????gV??&W67&?&??r??f?&?F???????vV?W&??&?6?f7F?'2f?"&?VVF??r??6?VFR??FW"vR???7F?'??b&?VVF??rF?6?&FW'2?W&f?&??6R?bW&7WF?V?W2??f6?fR&?6VGW&W2?B6??6??F?BW6R?b?VF?6F???2F?B??7&V6RF?R&?6??b&?VVF??r?R?r???F?6?wV??B?B??'&????F?2F?W&????v?W"F?6W2?b7?&????B6?&???2???7FW&??F??F?????&??F?'?G'Vw2??4?E5??v?V??76?&?R?F?66??F??VR%$???D??fRF?2&??"F?7W&vW'??7W7V7B&?VVF??r????F?V?Bv???2???FV?6?fR?B?2&V6V?F?V?FW&v??R6?&??'??v??w&???4??4$r??"?F?W"7W&v?6?&?6VGW&W2?WfV??bF?RF?V?BF?W2??B?fR??6?v?2?b&?VVF??r??b?76?&?R???vR&?VVF??rv?F??WBF?66??F??V??r%$???D?7F???r%$???D??7&V6W2F?R&?6??b7V'6WVV?B6&F??f67V?"WfV?G2?6VRv&???w2?B&V6WF???2?R?R??BGfW'6R&V7F???2?b????gV??&W67&?&??r??f?&?F?????6??6??F?B7?&?????FV??6RF?6R???D??W6R?b%$???Dv?F????FV??6RF?6W2?b7?&??&?fR?rFV7&V6VBF?RVffV7F?fV?W72?b%$???D?F?W&Vf?&R?gFW"F?R???F????F??rF?6R?b7?&???W7V??3#R?r??W6R%$???Dv?F????FV??6RF?6R?b7?&???bsR??r?6VRF?6vR?BF???7G&F????B6???6?7GVF?W2?B???gV??&W67&?&??r??f?&?F???????FW&FR?WF?2???&?V?B%$???D?2??B&VV?7GVF?VB??F?V?G2v?F???FW&FR?WF?2???&?V?B?6??6?FW"F?R&?6?2?B&V?^??G2?bG&VF?V?B???F??rF?R&?&&?R??7&V6R??W??7W&RF?F?6w&V??"???V??VB&FW2?b&?VVF??r&R7V??&??VB??F&?R&V??r?&?WB??b?bF?R&?VVF??rWfV?G2vW&R??F?Rf?'7B3F?2?F&?R????4$r&V?FVB&?VVG2???R?%$???D6???F?w&V???#3R???bF?F?????"????"???rr????"B?R2??fF???fR?F?&VFV???r"???fF??"?"??G&7&????fF???fR?F?&VFV???r??2?"26??v???F&?R?%$???Dv276?6?FVBv?F?6??Wv?Bw&VFW"&?6??b????4$r&?VVF??rF??v26???F?w&V????&6V??RFV??w&??2f7F?"?FW&VBF?R&V?F?fR&?6??b&?VVF??rv?F?%$???D6??&VBF?6???F?w&V?????D??S?BF?V?G2V?FW'vV?B4$r7W&vW'??F?RW&6V?FvW2?bF??6RF?V?G2v??&?VB&R6??v???F&?R"?&FW2vW&RfW'???v?'WB6???"f?"%$???D?B6???F?w&V??55t??D?5??s2???FB@??????2S?C???